The shares of Natco Pharma jumped more than 6 percent on October 10 after the Delhi High Court dismissed Swiss pharma giant Roche's appeal and allowed the Indian company to sell the spinal muscular atrophy (SMA) drug Risdiplam in India.

Roche had filed an appeal at the High Court against a single-judge order passed in March 2025 that had denied an injuction on Natco's sale of the drug in India.


The previous order had noted that the life-saving therapy must remain affordable and accessible. The March order had paved the way for Natco to launch the generic version of Roche's 'Risdiplam' drug.

The single judge bench had factored the challenge of invalidity of Roche's patent and laid special emphasis on the public interest, considering the Swiss company's pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients, Natco said in a statement.

After the division bench of the Delhi High Court dismissed Roche's appeal, Natco said that it has decided to launch the product with immediate effect at an MRP of Rs 15,900. "The Company also intends to offer some discount to certain deserving patients through its patient access programme," it added.